Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish R Patel

Showing results (61-70 of 167) with videos related to

Pageof 17
Sort By:
Investigational New Drugs|November 24, 2020
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancerBlake A Jacobson, Zeeshan Ahmad, Sierra Chen, et al.
Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.
Cancer|February 23, 2018
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trialsKaren Kelly, Jeffrey R Infante, Matthew H Taylor, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
British Journal of Clinical Pharmacology|March 25, 2020
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumoursDevalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumorsJohn L Villano, Jason J Luke, Ricklie Julian, et al.
Clinical Pharmacology in Drug Development|May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid TumorsGeoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Measles vaccine strains for virotherapy of non-small-cell lung carcinomaManish R Patel, Blake A Jacobson, Holly Belgum, et al.
Plos One|November 22, 2013
Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotideBlake A Jacobson, Saritha C Thumma, Joseph Jay-Dixon, et al.
Molecular Cancer Therapeutics|May 28, 2021
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMark D Pegram, Erika P Hamilton, Antoinette R Tan, et al.
Pageof 17

Showing results (61-70 of 167) with videos related to

Sort By:
Pageof 17
Investigational New Drugs|November 24, 2020
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancerBlake A Jacobson, Zeeshan Ahmad, Sierra Chen, et al.
Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.
Cancer|February 23, 2018
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trialsKaren Kelly, Jeffrey R Infante, Matthew H Taylor, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
British Journal of Clinical Pharmacology|March 25, 2020
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumoursDevalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumorsJohn L Villano, Jason J Luke, Ricklie Julian, et al.
Clinical Pharmacology in Drug Development|May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid TumorsGeoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Measles vaccine strains for virotherapy of non-small-cell lung carcinomaManish R Patel, Blake A Jacobson, Holly Belgum, et al.
Plos One|November 22, 2013
Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotideBlake A Jacobson, Saritha C Thumma, Joseph Jay-Dixon, et al.
Molecular Cancer Therapeutics|May 28, 2021
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMark D Pegram, Erika P Hamilton, Antoinette R Tan, et al.
Pageof 17